- Home
- BYSI vs JSPR Comparison
BYSI vs JSPR Comparison
Compare BYSI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- JSPR
- Stock Information
- Founded
- BYSI 2010
- JSPR 2018
- Country
- BYSI United States
- JSPR United States
- Employees
- BYSI N/A
- JSPR N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYSI Health Care
- JSPR Health Care
- Exchange
- BYSI Nasdaq
- JSPR Nasdaq
- Market Cap
- BYSI 72.1M
- JSPR 85.8M
- IPO Year
- BYSI 2017
- JSPR N/A
- Fundamental
- Price
- BYSI $1.68
- JSPR $4.52
- Analyst Decision
- BYSI
- JSPR Strong Buy
- Analyst Count
- BYSI 0
- JSPR 10
- Target Price
- BYSI N/A
- JSPR $62.50
- AVG Volume (30 Days)
- BYSI 32.9K
- JSPR 155.7K
- Earning Date
- BYSI 04-14-2022
- JSPR 05-20-2025
- Dividend Yield
- BYSI N/A
- JSPR N/A
- EPS Growth
- BYSI N/A
- JSPR N/A
- EPS
- BYSI N/A
- JSPR N/A
- Revenue
- BYSI N/A
- JSPR N/A
- Revenue This Year
- BYSI N/A
- JSPR N/A
- Revenue Next Year
- BYSI N/A
- JSPR N/A
- P/E Ratio
- BYSI N/A
- JSPR N/A
- Revenue Growth
- BYSI N/A
- JSPR N/A
- 52 Week Low
- BYSI $0.98
- JSPR $3.13
- 52 Week High
- BYSI $3.63
- JSPR $26.84
- Technical
- Relative Strength Index (RSI)
- BYSI 52.97
- JSPR 46.13
- Support Level
- BYSI $1.64
- JSPR $4.27
- Resistance Level
- BYSI $2.14
- JSPR $5.67
- Average True Range (ATR)
- BYSI 0.18
- JSPR 0.43
- MACD
- BYSI 0.03
- JSPR -0.01
- Stochastic Oscillator
- BYSI 44.58
- JSPR 22.56
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.